Suppr超能文献

高总剂量与分次剂量同步调强加速放疗联合或不联合化疗治疗老年鼻咽癌(NPC)患者的长期生存及晚期毒性反应(论文)重印版

Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.

作者信息

Miao Jingjing, Wang Lin, Zhu Manyi, Xiao Weiwei, Wu Haijun, Di Muping, Huang Yuqing, Huang Shaomin, Han Fei, Deng Xiaowu, Guo Xiang, Zhao Chong

机构信息

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China.

出版信息

Oral Oncol. 2019 Mar;90:126-133. doi: 10.1016/j.oraloncology.2019.01.005. Epub 2019 Jan 25.

Abstract

BACKGROUND

To analyse the survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by intensity-modulated radiotherapy (IMRT) with the high-total- and fractionated-dose simultaneous modulated accelerated radiation therapy (SMART) boost technique and to identify the effect of concurrent chemotherapy for these patients.

METHODS

Two hundred and fifty-four elderly patients (age ≥ 60.0) with newly diagnosed non-metastatic NPC were retrospectively analysed. Statistical analyses were performed using the SPSS software program.

RESULTS

The actual mean total and fractionated doses delivered to the gross tumour volume of the nasopharynx (GTVnx) were 74.55 Gy and 2.49 Gy, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) of the whole cohort were 93.0%, 85.7%, 83.2% and 74.1%, respectively. No grade 4 acute or late radiotherapy-induced toxicities were observed. Of 247 patients with stage II-IVb disease, 89 patients received radiotherapy (RT) alone, and 158 patients received concurrent chemoradiotherapy (CCRT), and the 5-year LRRFS, DMFS, DSS and OS of the RT-alone group vs. the CCRT group were 94.0% vs. 92.2%, 83.5% vs. 86.2%, 81.8% vs. 83.1% and 74.0% vs. 72.8% (all P > 0.05), respectively. Multivariate analyses showed that CCRT was not an independent predictor for LRRFS, DMFS, DSS and OS (all P > 0.05).

CONCLUSION

High-total- and fractionated-dose SMART boost IMRT could obtain a satisfactory long-term outcome with mild late toxicity in elderly NPC patients. The role of CCRT needs to be further studied to optimize the treatment strategy and improve the overall survival.

摘要

背景

分析采用高总量和分次剂量同步调强加速放疗(SMART)推量技术的调强放疗(IMRT)治疗老年鼻咽癌(NPC)患者的生存情况和晚期毒性反应,并确定同期化疗对这些患者的影响。

方法

回顾性分析254例年龄≥60.0岁的新诊断非转移性NPC老年患者。使用SPSS软件程序进行统计分析。

结果

鼻咽部大体肿瘤体积(GTVnx)实际接受的平均总剂量和分次剂量分别为74.55 Gy和2.49 Gy。整个队列的5年局部区域无复发生存率(LRRFS)、远处转移无复发生存率(DMFS)、疾病特异性生存率(DSS)和总生存率(OS)分别为93.0%、85.7%、83.2%和74.1%。未观察到4级急性或晚期放疗引起的毒性反应。在247例II-IVb期疾病患者中,89例仅接受放疗(RT),158例接受同期放化疗(CCRT),单纯放疗组与同期放化疗组的5年LRRFS、DMFS、DSS和OS分别为94.0%对92.2%、83.5%对86.2%、81.8%对83.1%和74.0%对72.8%(所有P>0.05)。多因素分析显示,CCRT不是LRRFS、DMFS、DSS和OS的独立预测因素(所有P>0.05)。

结论

高总量和分次剂量的SMART推量IMRT可使老年NPC患者获得满意的长期疗效,且晚期毒性反应较轻。CCRT的作用需要进一步研究,以优化治疗策略并提高总生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验